Literature DB >> 2110813

In vitro beta 2-microglobulin (beta 2m) secretion by normal and leukaemic B-cells: effects of recombinant cytokines and evidence for a differential response to the combined stimulus of phorbol ester and calcium ionophore.

R A Jones1, H G Drexler, S M Gignac, J A Child, C S Scott.   

Abstract

Due to the increasing therapeutic use of immunoregulatory agents and the potential effects on cellular function, we examined the modulation of in vitro beta 2-microglobulin (beta 2m) production rates by 'normal' tonsil and leukaemic B-cells in response to a number of these agents. Tonsil B-cells responded to phorbol ester (TPA) by an increased beta 2m production rate, which was further enhanced by the combined stimuli of TPA plus the calcium ionophore A23187. In marked contrast, however, lymphocytes from a majority (8/11) of B-cell malignancies showed a suppression of the TPA-induced beta 2m production rate in response to the combined TPA/A23187 stimulus. These different responses of 'normal' and malignant B-cells were not apparent when IgM production rates were examined. The recombinant cytokines IL-1, IL-2, IFN-alpha, IFN-gamma and TNF also enhanced beta 2m production rates of both normal and leukaemic B-cells, but to a considerably lesser extent than did TPA. Bryostatin-1 increased beta 2m production to a level intermediate between that obtained by TPA and the cytokines. It is suggested that beta 2m production rates may correspond to the degree of B-cell differentiation, and/or to the degree of cellular 'activation'. The results further indicate that the in vitro measurement of beta 2m production provides a different index of the cellular response than that obtained by the conventional measurement of IgM production.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2110813      PMCID: PMC1971599          DOI: 10.1038/bjc.1990.153

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  26 in total

1.  Proliferative response of hairy cells to B cell growth factor (BCGF): in vivo inhibition by interferon-alpha and in vitro effects of interferon-alpha, -beta, and -gamma.

Authors:  E Genot; C Billard; F Sigaux; C Mathiot; L Degos; E Falcoff; J P Kolb
Journal:  Leukemia       Date:  1987-08       Impact factor: 11.528

Review 2.  Protein kinase C as the receptor for the phorbol ester tumor promoters: sixth Rhoads memorial award lecture.

Authors:  P M Blumberg
Journal:  Cancer Res       Date:  1988-01-01       Impact factor: 12.701

Review 3.  Serum beta 2 microglobulin in multiple myeloma. A critical review.

Authors:  R Bataille; J Grenier
Journal:  Eur J Cancer Clin Oncol       Date:  1987-12

4.  Leukemia diagnosis and testing of complement-fixing antibodies for bone marrow purging in acute lymphoid leukemia.

Authors:  D Campana; G Janossy
Journal:  Blood       Date:  1986-12       Impact factor: 22.113

5.  Treatment of hairy cell leukemia with alpha interferons.

Authors:  J R Quesada; J U Gutterman; E M Hersh
Journal:  Cancer       Date:  1986-04-15       Impact factor: 6.860

6.  The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia. I. Clinical and laboratory features of 300 patients and characterization of an intermediate group.

Authors:  J V Melo; D Catovsky; D A Galton
Journal:  Br J Haematol       Date:  1986-06       Impact factor: 6.998

7.  Triggering of neoplastic B cells via surface IgM and the cell surface antigens CD20 and CDw40. Responses differ from normal blood B cells and are restricted to certain morphologic subsets.

Authors:  K Beiske; E A Clark; H Holte; J A Ledbetter; E B Smeland; T Godal
Journal:  Int J Cancer       Date:  1988-10-15       Impact factor: 7.396

8.  Analysis of signal transduction in B chronic lymphocytic leukemia cells.

Authors:  H G Drexler; M K Brenner; E Coustan-Smith; S M Gignac; A V Hoffbrand
Journal:  Blood       Date:  1988-05       Impact factor: 22.113

9.  Activation of malignant B-lymphocytes: pathophysiologic and clinical importance.

Authors:  K H Robèrt; G Juliusson; S Einhorn; P Biberfeld; G Gahrton
Journal:  Scand J Haematol       Date:  1986-11

10.  Tumor necrosis factor enhances HLA-A,B,C and HLA-DR gene expression in human tumor cells.

Authors:  K Pfizenmaier; P Scheurich; C Schlüter; M Krönke
Journal:  J Immunol       Date:  1987-02-01       Impact factor: 5.422

View more
  2 in total

1.  Genes expressed in the mouse pituitary corticotrope AtT-20/D-16v tumor cell line.

Authors:  M R Schiller
Journal:  Pituitary       Date:  2000-11       Impact factor: 4.107

2.  A phase I study of intravenous bryostatin 1 in patients with advanced cancer.

Authors:  J Prendiville; D Crowther; N Thatcher; P J Woll; B W Fox; A McGown; N Testa; P Stern; R McDermott; M Potter
Journal:  Br J Cancer       Date:  1993-08       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.